Anhui Anke Biotechnology (Group) Co., Ltd.

Informe acción SZSE:300009

Capitalización de mercado: CN¥15.3b

Anhui Anke Biotechnology (Group) Crecimiento futuro

Future controles de criterios 2/6

Anhui Anke Biotechnology (Group) is forecast to grow earnings and revenue by 16.7% and 10.6% per annum respectively. EPS is expected to grow by 16.1% per annum. Return on equity is forecast to be 21.5% in 3 years.

Información clave

16.7%

Tasa de crecimiento de los beneficios

16.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs44.8%
Tasa de crecimiento de los ingresos10.6%
Rentabilidad financiera futura21.5%
Cobertura de analistas

Low

Última actualización01 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price Is Matching Sentiment Around Its Earnings

Sep 25
Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price Is Matching Sentiment Around Its Earnings

Anhui Anke Biotechnology (Group) (SZSE:300009) Will Pay A Dividend Of CN¥0.25

May 23
Anhui Anke Biotechnology (Group) (SZSE:300009) Will Pay A Dividend Of CN¥0.25

Earnings Working Against Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price

Mar 01
Earnings Working Against Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price

Previsiones de crecimiento de beneficios e ingresos

SZSE:300009 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20263,5661,2611,3361,4271
12/31/20253,2641,1489511,2981
12/31/20242,9821,0481,1851,1701
9/30/20242,766783596748N/A
6/30/20242,877867633826N/A
3/31/20242,928879713892N/A
12/31/20232,866847758953N/A
9/30/20232,646763472883N/A
6/30/20232,538755359796N/A
3/31/20232,392716291751N/A
1/1/20232,331703225699N/A
9/30/20222,328372385632N/A
6/30/20222,280307448636N/A
3/31/20222,217254471673N/A
12/31/20212,169207461592N/A
9/30/20212,096489509628N/A
6/30/20211,959441388509N/A
3/31/20211,871403387492N/A
12/31/20201,701359326465N/A
9/30/20201,702167237400N/A
6/30/20201,661140221378N/A
3/31/20201,681140161343N/A
12/31/20191,713124109296N/A
9/30/20191,60728948257N/A
6/30/20191,598280-24239N/A
3/31/20191,52927016258N/A
12/31/20181,46226374287N/A
9/30/20181,382317105286N/A
6/30/20181,276292N/A322N/A
3/31/20181,177290N/A305N/A
12/31/20171,096278N/A281N/A
9/30/20171,009249N/A285N/A
6/30/2017941228N/A254N/A
3/31/2017878209N/A243N/A
12/31/2016849197N/A258N/A
9/30/2016751169N/A169N/A
6/30/2016696160N/A148N/A
3/31/2016671148N/A144N/A
12/31/2015636136N/A119N/A
9/30/2015629137N/A124N/A
6/30/2015609127N/A120N/A
3/31/2015579115N/A116N/A
12/31/2014542110N/A109N/A
9/30/2014509107N/A76N/A
6/30/201447299N/A67N/A
3/31/201444894N/A48N/A
12/31/201343090N/A53N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 300009's forecast earnings growth (16.7% per year) is above the savings rate (2.9%).

Beneficios vs. Mercado: 300009's earnings (16.7% per year) are forecast to grow slower than the CN market (25.8% per year).

Beneficios de alto crecimiento: 300009's earnings are forecast to grow, but not significantly.

Ingresos vs. Mercado: 300009's revenue (10.6% per year) is forecast to grow slower than the CN market (14% per year).

Ingresos de alto crecimiento: 300009's revenue (10.6% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 300009's Return on Equity is forecast to be high in 3 years time (21.5%)

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y